Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   INTERNATIONAL JOURNAL OF HEMATOLOGY-ONCOLOGY AND STEM CELL RESEARCH (IJHOSCR)   APRIL 2016 , Volume 10 , Number 2; Page(s) 115 To 119.
 
Paper: 

APPROACH TO THE TRIPLE NEGATIVE BREAST CANCER IN NEW DRUGS AREA

 
 
Author(s):  MIRZANIA MEHRZAD*
 
* HEMATOLOGY AND MEDICAL ONCOLOGY DEPARTMENT, CANCER RESEARCH CENTER, CANCER INSTITUTE OF IRAN, IMAM KHOMEINI HOSPITAL COMPLEX, TEHRAN UNIVERSITY OF MEDICAL SCIENCES, TEHRAN, IRAN
 
Abstract: 

Triple negative breast cancers (TNBCs) are associated with aggressive course, higher rates of visceral and central nervous system metastases and lower survival rate than hormone receptor positive. Once metastasis has occurred, a median survival was approximately one year. Currently, chemotherapy in TNBC is similar to other HER2- negative breast cancers but in the near future, it will revolutionize. TNBCs are quite heterogeneous based on biomarkers and genetic variations. The series of new drugs have been tried; in this article, platinum, anti-epigenetic drugs, PARP inhibitors, epidermal growth factor receptor inhibitor, Src family kinase inhibitor, anti-androgen, glycoprotein Non-metastatic melanoma B (gpNMB) antibody, LHRH conjugated to cytotoxic drugs and inhibition of the PI3K/AKT/mTOR pathway will be explained. What is the optimal therapy for TNBC patients? It is still not clear but it seems that the road map according to biological and genetic markers is taking shape.

 
Keyword(s): TRIPLE NEGATIVE BREAST CANCERS, PARP INHIBITORS, GPNMB, SRC FAMILY KINASE, PI3K/AKT/MTOR PATHWAY
 
References: 
  • ندارد
 
  pdf-File tarjomyar Yearly Visit 84
 
Latest on Blog
Enter SID Blog